. Author manuscript; available in PMC: 2021 Jan 1.

Published in final edited form as: Breast Cancer Res Treat. 2019 Oct 10;179(1):229–240. doi: 10.1007/s10549-019-05457-9

Table 3.

dietary fat intake trajectory following a breast cancer diagnosis

Predictors	Low maintainer¹(n=256)	Medium-low maintainer (n=1,336)		Medium-high maintainer (n=1,142)		High maintainer(n=131)

		OR (95% CI)	P	OR (95% CI)	P	OR (95% CI)	P

Education (ref=high school or less)
Some college	Ref	1.09 (0.6 1, 1.92)	0.78	0.91 (0.51, 1.61)	0.74	0.91 (0.38, 2.16)	0.83
College and above	Ref	1.22 (0.70, 2.14)	0.48	0.89 (0.51, 1.57)	0.70	0.79 (0.33, 1.86)	0.59
Income (ref=<$50K)
$50K-$89K	Ref	1.06 (0.72, 1.58)	0.76	1.11 (0.75, 1.66)	0.60	1.46 (0.79, 2.71)	0.22
$90K+	Ref	1.67 (0.86, 3.26)	0.13	1.03 (0.51, 2.05)	0.94	t 1.02 (0.33, 3.21)	0.97
Depressive symptoms (high vs. low)	Ref	1.12 (0.70, 1.78)	0.63	0.99 (0.62, 1.59)	0.98	1.13 (0.55, 2.31)	0.74
Optimism (high vs. low)	Ref	0.91 (0.63, 1.33)	0.63	0.78 (0.53, 1.15)	0.52	1.43 (0.79, 2.57)	0.24
Social support (high vs. low)	Ref	0.85 (0.57, 1.27)	0.42	0.88 (0.58, 1.31)	0.02	0.86 (0.46, 1.61)	0.63
Worse PWB at 6 months (yes vs. no)	Ref	0.58 (0.38, 0.89)	0.01	0.61 (0.40, 0.94)		0.80 (0.42, 1.56)	0.52
Worse CIPN at 6 months (yes vs. no)	Ref	1.53 (1.00, 2.33)	0.05	1.66 (1.08, 2.56)	0.02	1.53 (0.80, 2.94)	0.20
Age at diagnosis (ref=age<50)
50–59	Ref	1.04 (0.51, 2.11)	0.91	0.74 (0.36, 1.52)	0.42	1.88 (0.56, 6.35)	0.31
60–70	Ref	0.80 (0.34, 1.87)	0.60	0.78 (0.33, 1.84)	0.57	1.47 (0.37, 5.94)	0.59
70+	Ref	0.67 (0.27, 1.64)	0.38	0.62 (0.25, 1.55)	0.31	0.77 (0.17, 3.47)	0.73
Race/ethnicity (ref=non-Hispanic White)
non-Hispanic Black	Ref	1.42 (0.58, 3.49)	0.44	1.37 (0.55, 3.40)	0.49	2.24 (0.70, 7.13)	0.17
non-Hispanic Asian	Ref	1.76 (0.88, 3.49)	0.11	2.37 (1.19, 4.73)	0.01	3.37 (1.31, 8.65)	0.01
Hispanic	Ref	1.06 (0.58, 1.96)	0.85	1.06 (0.57, 1.97)	0.86	0.83 (0.29, 2.35)	0.73
Other	Ref	1.46 (0.41, 5.15)	0.56	1.90 (0.54, 6.62)	0.32	0.77 (0.08, 7.85)	0.82
Postmenopausal (yes vs. no)	Ref	0.99 (0.50, 1.95)	0.98	1.00 (0.50, 1.99)	0.99	1.55 (0.54, 4.40)	0.41
Baseline BMI (ref=BMI <25 kg/m²)
Overweight (BMI 25–29.9 kg/m²)	Ref	1.33 (0.89, 2.00)	0.17	1.60 (1.06, 2.43)	0.03	1.21 (0.59, 2.47)	0.60
Obese (BMI 30+ kg/m²)	Ref	1.47 (0.93, 2.33)	0.10	2.53 (1.60, 4.01)	<0.01	3.04 (1.54, 6.02)	<0.01
Stage (ref=Stage I)
Stage II	Ref	1.02 (0.65, 1.61)	0.92	1.38 (0.88, 2.17)	0.16	1.08 (0.52, 2.22)	0.84
Stage III	Ref	0.90 (0.43, 1.89)	0.78	0.99 (0.47, 2.08)	0.97	1.86 (0.62, 5.58)	0.27
Stage IV	Ref	2.23 (0.33, 14.9)	0.41	0.58 (0.08, 4.32)	0.59	NE	NE
Number of lymph node removed (ref=0)
1	Ref	1.60 (0.5 8, 4.41)	0.36	0.85 (0.32, 2.28)	0.75	0.75 (0.15, 3.76)	0.73
2+	Ref	1.57 (0.60, 4.11)	0.36	1.02 (0.40, 2.60)	0.96	0.78 (0.17, 3.63)	0.76
ER/PR status (Positive vs. negative)	Ref	0.41 (0.19, 0.90)	0.03	0.51 (0.23, 1.14)	0.10	0.34 (0.11, 1.10)	0.07
Surgery (ref=lumpectomy)
Mastectomy	Ref	0.90 (0.60, 1.36)	0.62	1.09 (0.72, 1.66)	0.67	1.27 (0.67, 2.41)	0.47
None	Ref	0.16 (0.02, 1.56)	0.11	0.69 (0.09, 5.33)	0.72	NE	NE
Chemotherapy (ref=none)
Neoadjuvant	Ref	0.64 (0.21, 1.90)	0.42	0.78 (0.27, 2.30)	0.66	0.29 (0.05, 1.70)	0.170.20
Adjuvant	Ref	0.90 (0.56, 1.45)	0.66	0.86 (0.53, 1.40)	0.55	0.60 (0.28, 1.31)	0.20
Hormonal therapy (yes vs. no)	Ref	1.10 (0.63, 1.94)	0.73	1.08 (0.61, 1.93)	0.78	0.91 (0.36, 2.30)	0.84
Radiation (yes vs. no)	Ref	0.89 (0.59, 1.35)	0.58	0.83 (0.54, 1.26)	0.38	1.01 (0.52, 1.94)	0.98

Note

Abbreviations: OR, odds ratio; CI, confidence interval; BMI, body mass index; CIPN, chemotherapy-induced peripheral neuropathy; PWB, physical well-being; NE, not estimable

^1.

Trajectory groups were labeled by the relative level of baseline behavior (high, medium, or low), direction of change (increased, unchanged, or decreased), and the persistence of change (temporary or stable).